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Abstract. – BACKGROUND: The objective of
the current study was to evaluate the role of var-
ious inflammatory biomarkers in detection of
coronary stenosis in patients with stable coro-
nary artery disease (CAD) and healthy people.
METHODS: A total of 111 patients with stable
coronary artery disease, and 66 healthy subjects
were enrolled in the study. Serum levels of
lipoprotein-associated-phospholipase A2 (Lp-
PLA2), high-sensitivity C-reactive protein (hs-
CRP), and myeloperoxidase (MPO) were mea-
sured to compare patient and control groups. 
RESULTS: Baseline characteristics were simi-
lar between healthy and patient groups, with the
exception of age. ANCOVA and log-transformed
data of inflammatory biomarkers revealed that,
Lp-PLA2 (p < 0,001) and hs-CRP (p < 0,05) levels
in all patient groups were significantly higher
than in the control group. Conversely, there was
no significant difference in MPO levels among
groups.
CONCLUSIONS: In stable CAD patients, serum
Lp-PLA2 levels are more compatible than hs-
CRP and MPO levels in the detection of coronary
stenosis.
Key Words:
Atherosclerosis, Coronary artery disease, Lp-PLA2,
MPO, hsCRP.
Introduction
Atherosclerosis is a multifactorial disease, and
inflammation plays an important role in athero-
genesis and plaque vulnerability1. It has been es-
tablished that vulnerable plaques are the underly-
ing cause of most coronary events. It is important
to identify patients at risk of coronary artery dis-
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ease (CAD) for clinical diagnosis, treatment and
prognosis. Because conventional risk factors do
not explain the changes in atherosclerosis, efforts
to identify vulnerable plaques have focused on
developing novel biomarkers2. 
Lipoprotein-associated phospholipase A2 (Lp-
PLA2) is an enzyme that degrades oxidized phos-
pholipids into low density lipoprotein cholesterol
(LDL-C), leading to the formation of proinflam-
matory and cytotoxic products. Because of its
high specificity for vascular inflammation, it is a
novel biomarker and has been identified as a po-
tential novel therapeutic target. Experimental
studies have shown a direct causal link between
Lp-PLA2-mediated pathways and plaque inflam-
mation and rupture. It is commonly seen in ad-
vanced rupture-prone and ruptured plaques3. 
C-reactive protein (CRP) is an acute phase re-
actant that is found in circulation. CRP is synthe-
sized by the liver in response to factors released
by adipocytes (TNF-alfa and other adipocy-
tokines). It is a non-specific biomarker, and it can
become elevated due to many non-cardiac in-
flammation. Because CRP cannot show where
the inflammation is located in the body, other
tests are needed to find the cause and location of
the inflammation. Studies showed that higher
than 2.4 mg/l high-sensitivity CRP (hs-CRP) lev-
els have been associated with a doubling of risk
for coronary events4. CRP should be measured as
hs-CRP when assessing cardiovascular risk be-
cause it is designed for greater accuracy in mea-
suring very low levels of CRP.
Myeloperoxidase (MPO) is a leukocyte-de-
rived enzyme that is essential for immune system
and inflammatory process. Several mechanisms
may explain the proatherogenic effects of MPO,
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including LDL oxidation, inactivation of HDL,
endothelial dysfunction due to a decrease of ni-
tric oxide bioavailability, activation of metallo-
proteinase 7, and an increase in vascular cell
apoptosis5. 
The aim of this study was to compare Lp-
PLA2, MPO and hs-CRP levels in the detection




A total of 224 patients (154 men and 70
women) suffering from chest discomfort (range:
35-85 years, average 57 years) were enrolled in
the study. Out of these 224, 158 were scheduled
for coronary angiography because of suspected
CAD based on non-invasive assessment. Patients
with symptoms of unstable CAD within the last
month were excluded to avoid the influence of an
acute coronary episode. Exclusion criteria in-
cluded ongoing infections and autoimmune or
other acute inflammatory conditions. Forty-seven
patients were later excluded because of cancelled
angiography, aforementioned illness or missed
blood sampling. An angiographic analysis of the
111 subjects was performed by the investigators.
The severity of coronary stenosis was estimated
by visual determination. CAD was diagnosed if
there was at least one lesion with > 50% stenosis
in luminal diameter on coronary angiography ac-
cording to the American College of Cardiolo-
gy/American Heart Association lesion classifica-
tion. Lesions were classified into the four groups
according to the number of affected vessels: nor-
mal coronary angiogram or 1, 2 or 3 vessel dis-
eases. A total of 66 healthy volunteers were used
as the control group, and angiography was per-
formed on 32% of them based on non-invasive
diagnostic assessment.
Risk factors including high blood pressure,
fasting blood glucose level, smoking and lipid
status were assessed at the time of enrollment.
Diabetes was defined as fasting serum glucose
values ≥ 126 mg/dL on 2 or more occasions, or
2-hour serum glucose level > 200 mg/dL after an
oral glucose tolerance test. Participants were ac-
cepted as hypertensive if they had a blood pres-
sure ≥ 140/90 mmHg on two or more occasions
or were already on antihypertensive therapy. If
the patients had been given lipid-lowering thera-
py or had a history of total cholesterol levels >
240 mg/dL, they were accepted as hyperlipidem-
ic. The research was approved by the local Ethics
Committee, and all participants gave written in-
formed consent before entering the study.
Laboratory Analysis
Blood samples were run after an overnight fast-
ing of 12 h, and sera were separated by low-speed
centrifugation for 15 min. Samples were immedi-
ately stored at -85°C for biomarkers. Levels of
serum total cholesterol (TC) and serum triglyc-
erides (TG) were estimated by enzymatic methods
using an Abbot Architect C16000 autoanalyzer
(Diamond Diagnostics Inc, Boston, MA, USA)
with original reagents. HDL-C was measured by
the dextran sulfate-Mg+2 precipitation method,
whereas LDL-C was calculated by the Friede-
wald’s formula. Apolipoprotein A-I (Apo A-I) and
apoprotein B (Apo B) levels were assessed by im-
munonephelometry using Date Behring (BN II,
Marburg, Germany) and its original reagent. The
results are expressed in mg/dl of serum. 
Biomarker Analysis
Lp-PLA2 mass was determined in serum by a
dual monoclonal antibody immunoassay stan-
dardized to the recombinant PAF-AH PLAC test
(diaDexus Inc, San Francisco, CA, USA)6. The
assay range is 1-1000 ng/mL, and the median
value in healthy adults is 218 µg/L. Plasma hs-
CRP levels were measured by an immunoturbidi-
metric method using a commercially available kit
(Beckman Coulter, Krefeld, Germany) with the
manufacturer’s reagents. The detection limit for
hs-CRP was 0.02 mg/L; intra- and inter-assay co-
efficients of variations were 5.2%. MPO concen-
trations were measured in plasma using a sand-
wich ELISA for human MPO according to the
manufacturer’s protocol (Hycult Biotechnology
(Hycult Biotechnology (Hycult Biotech Inc,
Uden, the Netherlands). The intra-assay coeffi-
cient of variance was < 10%. All plasma samples
were analyzed in duplicate in the same run. 
Statistical Analysis
Data are presented as the mean±SD for nor-
mally distributed continuous variables, as the
median (IQR) for non-normally distributed con-
tinuous variables and as percentages for categori-
cal variables. Normality was tested using the
Kolmogorov-Smirnov test. hs-CRP and MPO
were not normally distributed; therefore, these
values were logarithmically transformed in order
to approach normal distribution and obtain equal
113
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Healthy 1 vessel 2 vessels 3 vessels 
control plugged plugged plugged
Parameters (n: 66) (n: 31) (n: 54) (n: 26)
Age (year) 53 ± 12 60 ± 8a* 63 ± 10b*** 60 ± 8c*
BMI (kg/m2) 30 ± 5 30 ± 6 29 ± 4 29 ± 3
Waist circumference (cm) 106 ± 13 104 ± 12 102 ± 12 101 ± 10
Gensini Score 18 ± 19 32 ± 26 35 ± 43 33 ± 38
Gender, male, n (%) 39 (59) 16 (52) 39 (72) 23 (89)c*e*
Hypertension, n (%) 14 (30) 18 (58)a* 28 (52) 9 (35)
DM, n (%) 8 (12) 4 (13) 9 (17) 6 (23)
Smoking, n (%) 11 (17) 4 (13) 15 (28) 8 (31)
Dyslipidemia  n (%) 1 (2) 6 (21)a* 4 (8) 2 (8)
TC/HDL-C ≥ 4.5 27 (41) 18 (67) 31 (63) 19 (73)c*
TG (mg/dL) 122 ± 55 144 ± 66 143 ± 84 130 ± 60
TC (mg/dL) 177 ± 28 200 ± 45a* 187 ± 37 175 ± 41
LDL-C (mg/dL) 111 ± 24 129 ± 35a* 121 ± 32 117 ± 33 
HDL-C (mg/dL) 42 ± 10 41 ± 10 39 ± 12 32 ± 6c***e**f*
TC/HDL-C 4.49 ± 1.29 4.99 ± 1.36 5.23 ± 1.84b* 5.62 ± 1.55c***
Apo AI (mg/dL) 142 ± 28 161 ± 35 147 ± 31 137 ± 23e*
Apo B (mg/dL) 98 ± 18 106 ± 33 102 ± 27 96 ± 28
Apo B/Apo AI 0.71 ± 0.18 0.67 ± 0.18 0.73 ± 0.25 0.72 ± 0.25
Table I. Distribution of demographic features and lipid profiles in individuals with CAD in according to angiographic findings
and without.
Data are presented mean ± SD for normally distributed continuous variables and median (IQR) for non-normally distributed
continuous variables. Comparison of healthy control group vs (a) 1 vessel vs (b) 2 vessel vs (c) 3 vessel plugged; Comparison
of patients with 1 vessel plugged vs (d) 2 vessel, vs (e) 3 vessel plugged and comparison of patients with 2 vessel plugged vs
(f) 3 vessel plugged. *0.0 5 > p, **0.01 > p, ***0.005 > p.
markers and the demographic indices and per one
category variation in CAD severity. The specific
relationship between vessel disease and inflam-
matory markers was assessed by Spearman’s
rank correlation. A p value < 0.05 was consid-
ered to indicate statistical significance; all tests
were two-sided. The SPSS 16.0 statistical soft-
ware package (SPSS Inc, Chicago, IL, USA) was
used for all calculations.
Results
Participants were predominantly male and
overweight, and some were taking medications
for CAD, hypertension, dyslipidemia and dia-
betes. MPO measurements were not performed
in eleven patients due to technical problems.
Table I presents the results of unadjusted com-
parisons regarding baseline characteristics in four
subgroups that were divided based on the angio-
graphic findings involved in the study. The pa-
tients with diabetes mellitus and smoking were
similar among groups. Total cholesterol, LDL-C,
TC/HDL-C ≥4.5, hypertension, and male gender
variances. Analysis of variance (ANOVA) was
used to evaluate unadjusted differences in contin-
uous variables among the four groups. Jonck-
heere-Terpstra’s test was applied to evaluate
whether there were trends in the data with re-
spect to severity of coronary artery disease. Com-
parisons between categorical variables were per-
formed with a chi-square test or Fisher’s exact
test as appropriate. Analysis of variance with co-
variates (ANCOVA) was used to evaluate differ-
ences in inflammatory biomarker levels and bio-
chemistry indices between groups after adjust-
ment for all the variables that were significantly
different among the groups. The simple logistic
regression analysis was used to assess univariate
associations between the Lp-PLA2, hs-CRP,
MPO and CAD status as a number of vessel dis-
eases. In addition, a multiple logistic regression
analysis was used to assess the independent ad-
justed relationship between these indices and
CAD status with independent variables being
those that were significantly different among the
patient groups. Odd’s ratios (OR) with 95%
confidence intervals were calculated per one in-
crease in standard deviation of inflammatory
115
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in patients with at least 1 vessel disease were
higher than in the control group. The mean age
was higher in patient groups, whereas waist cir-
cumference, body mass index and Gensini score
were not significantly different. A significant de-
crease in HDL-C and apo AI levels was detected
in patients with 3-vessel disease compared to
those of the control group. However, plasma TG,
apo B levels and the ratio of apo B/AI did not
differ significantly among the study groups. 
An unadjusted comparison (ANOVA) revealed
that plasma Lp-PLA2 levels for all groups were
significantly higher than in the control group (p <
0.001), but hs-CRP levels were only higher in the
2-vessel disease group (Table II). Plasma MPO
levels were lower in the control group compared
to each vessel disease category, but this difference
was not significant. In patient groups, inflammato-
ry biomarker levels showed insignificant differ-
ences regardless of the number of vessels. 
Taking into account the differences among
groups (ANCOVA) and log-transformed data of
inflammatory biomarkers, Lp-PLA2 (p < 0.001)
and hs-CRP (p < 0.05) levels in all patient groups
remained significantly higher than in the control
group. Conversely, there was no significant differ-
ence in MPO levels among groups, after adjusting
for covariates including age, sex, hypertension,
diabetes, smoking, BMI, waist circumference and
TC/HDL-c ratio (p > 0.05) (Table II). Figure 1
demonstrates that there was a trend toward elevat-
ed plasma levels of Lp-PLA2 and hs-CRP in pa-
tients with a higher number of vessel disease,
with the exception of the 3-vessel disease group.
Although the level of Lp-PLA2 remained un-
changed (p < 0.001) after covariate adjustment,
the level of hs-CRP decreased (p < 0.05). 
As seen in Table III, the results of univariate
logistic regression analysis for each of the bio-
markers showed that Lp-PLA2 and hs-CRP para-
meters could discriminate CAD but not the
severity of the disease. Adjusted multiple logistic
regression analysis indicated that inflammatory
biomarker levels continued to be independently
associated with CAD presentation and confirmed
a failure to project disparity in the number of dis-
eased vessels.
Healthy 1 vessel 2 vessels 3 vessels 
control plugged plugged plugged
Parameters (n: 66) (n: 31) (n: 54) (n: 26)
Lp-PLA2 (µg/L) 249 ± 118 365 ± 82a** 375 ± 92b** 331 ± 115c**
hs-CRP (mg/L) 2.6 (0.3-17) 5.1 (0.2-26) 9.6 (0.4-48)b** 11.6 (0.5-40)c*
MPO (µg/L) 32 (61-269) 79 (32-686) 109 (19-876) 87 (4-482)
Distribution in multivariable adjusted model#
Log Lp-PLA2 (ng/mL) 2.25 (2.19-2.32) 2.55 (2.51-2.59)a** 2.59 (2.56-2.61)b** 2.57 (2.52-2.61)c**
Log hs-CRP (µg/dL) 2.24 (2.10-2.38) 2.45 (2.25-2.66)a* 2.61 (2.47-2.76)+* 2.60 (2.41-2.80)c*
Log MPO (µg/L) 2.04 (1.97-2.11) 1.98 (1.85-2.11) 2.01 (1.90-2.13) 1.89 (1.70-208)
Table II. Distribution of inflammatory biomarkers in individuals with CAD in according to angiographic findings and without.
Data are presented mean ± SD for normally distributed continuous variables and median (IQR) for non-normally distributed con-
tinuous variables. #For all inflammatory markers, analyses were performed on the means of log-transformed values with 95 %
confidence internal (Cl) and , the association between inflammatory  biomarkers levels with severity of coronary artery disease af-
ter adjustment for baseline factors including age, sex, hypertension diabetes, smoking, BMI, waist circumference and TC/HDL-C
ratio. Comparison of healthy control group vs (a) 1 vessel vs (b) 2 vessel vs (c) 3 vessel plugged *0.0 5 > p, **0.001 > p.
Figure 1. Mean (+SD) Log Lp-PLA2, Log hs-CRP and
Log MPO plasma levels in study group classified according
*There is statistically significant difference (p < 0.05);
**There is statistically significant difference (p < 0.001).
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Table IV summarizes the Spearman correla-
tion coefficients for inflammatory biomarkers
among the groups. In both 2-vessel disease and
all patient groups, Lp-PLA2 appeared to be posi-
tively associated with the variations of plasma
hs-CRP, and the association was clearer in latter
group (p < 0.01). This relationship was also
demonstrated in patients with CAD as shown in
Figure 2. Additionally, a positive correlation be-
tween plasma MPO and hs-CRP levels was ob-
served in all patient groups.
Discussion
Despite considerable progress in treating CAD,
it remains a major cause of mortality and morbidi-
ty across the world. Identifying those at risk is im-
portant for early diagnosis and treatment. Thus,
investigators have focused on promptly identifying
vulnerable plaques, which are responsible for
most of the coronary events7. 
In our study, we assessed the value of a num-
ber of inflammatory biomarkers – namely, Lp-
PLA2, hs-CRP, and MPO – in the detection of
coronary stenosis among healthy people and es-
tablished CAD patients. In addition, we analyzed
the diagnostic values of various biomarkers in
terms of CAD. 
Male gender was predominant in this investi-
gation. It was observed that CAD commonly oc-
curred in the male cohort, especially in younger
Variable Odd’s Ratio % 95 Cl p
Lp-PLA2 1.02 1.009-1.035 0.001
hs-CRP 19 0.100-3600 0.267
MPO 0.99 0.991-1.006 0.736
Multivariable adjusted model#
Lp-PLA2 74 8-720 0.002
hs-CRP 0.16 0.06-0.462 0.001
MPO 0.48 0.11-2.10 0.143
Table III. Prediction of CAD severity by univariate and multivariate logistic analysis for inflammatory marker levels in indi-
vidual with case (n = 111) and control (n = 66) groups.
Ors indicate relative risk for a change in one standard deviation. #Adjusted for age, sex, hypertension diabetes, smoking, BMI,
waist circumference and TC/HDL-C ratio.
Figure 2. Mean (+SD) Log Lp-PLA2, Log hs-CRP and
Log MPO plasma levels in study group classified according
*There is statistically significant difference (p < 0.05);
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Table IV. Spearman correlation coefficients for biomarkers
in study groups.
*There is statistically significant difference (p < 0.05);
**There is statistically significant difference (p < 0.01).
men. While the mean age was lower in the con-
trol group, smoking, diabetes and hypertension,
which are known coronary risk factors, were
similar between the control and patient groups.
Food habits were also an important factor in
terms of the development of CAD. TC/HDL-C
ratio was significantly higher in patient groups
than in the control due to very low HDL-C lev-
els, especially in the 3-vessel disease group (p <
000.5). A positive correlation between adipose
tissue level (BMI, waist circumference) and hs-
CRP was found. It was assumed that elevation of
hs-CRP might be due to vascular inflammation. 
Lp-PLA2 is a vascular-specific biomarker.
Many experimental and epidemiologic studies
have shown that elevated Lp-PLA2 levels are as-
sociated with an increased risk for initial coro-
nary events, recurrent coronary events and stroke
in secondary prevention6,8. The WOSCOPS
study, which referred to a male cohort with hy-
perlipidemia, demonstrated an association be-
tween Lp-PLA2 levels and coronary heart
disease9. This association was observed only in
patients with low cholesterol level in the ARIC
study10, whereas it was not an independent pre-
dictor of cardiovascular events in the Women’s
Health Study11. Conversely, Brikalis et al.12 found
increased Lp-PLA2 levels in patients with estab-
lished CAD and subsequent coronary events12. 
In our study, the Lp-PLA2 level was significant-
ly higher in all patients groups compared to the
control. This association was correlated with the
traditional risk factors, according to multiple logis-
tic regression analysis (p < 0.001), but was not cor-
related with the number of affected vessels. 
CRP, an acute phase reactant, may be a bio-
marker for proinflammatory milieu and a direct
risk factor for coronary events13. Currié et al4 con-
cluded that CRP was a relatively moderate predic-
tor of CAD. We observed significant positive cor-
relation between hs-CRP and the CAD group,
which was not associated with the risk factors for
CAD or the number of affected numbers. 
Another objective of this research was to as-
sess the association between MPO levels and the
severity of CAD. The increased MPO level is
now recognized as a powerful prognostic deter-
minant of myocardial infarction5,14. Although
they relied on a small group of patients, Duz-
gunçinar et al15 found a positive correlation be-
tween CAD severity and MPO levels assessed by
Gensini scoring. However, a great deal of other
studies revealed inconsistent results in terms of
severity and prognosis between CAD and MPO
levels16-19. Our findings agree with the aforemen-
tioned literature.
This study is limited by the heterogeneity of
the participants, especially in the control group
and in terms of the age of the patients. 
Conclusions
The likelihood ratios of MPO and hsCRP for
the diagnosis of premature coronary atheroscle-
rosis were lower than Lp-PLA2. Lp-PLA2 is a
more specific biomarker, and thus, it might be
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